Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in chemotherapy desensitization
NCT02118987Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of omalizumab in drug allergy, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Percentage of patients able to undergo reaction-free desensitizations at 2 years. Started Jul 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
drug allergy
Beyond the preview
Go deeper on NCT02118987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118987.